



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2017

Effect of β -lactamase production and β -lactam instability on MIC testing results for *Mycobacterium abscessus*

Rominski, Anna ; Schulthess, Bettina ; Müller, Daniel M ; Keller, Peter M ; Sander, Peter

DOI: <https://doi.org/10.1093/jac/dkx284>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-141751>

Journal Article

Published Version

Originally published at:

Rominski, Anna; Schulthess, Bettina; Müller, Daniel M; Keller, Peter M; Sander, Peter (2017). Effect of β -lactamase production and β -lactam instability on MIC testing results for *Mycobacterium abscessus*. *Journal of Antimicrobial Chemotherapy*, 72(11):3070-3078.

DOI: <https://doi.org/10.1093/jac/dkx284>

Effect of β -lactamase production and β -lactam instability on MIC testing results for *Mycobacterium abscessus*

Anna Rominski¹, Bettina Schulthess^{1,2}, Daniel M. Müller³, Peter M. Keller^{1,2} and Peter Sander^{1,2*}

¹Institut für Medizinische Mikrobiologie, Universität Zürich, Gloriastrasse 30/32, 8006 Zürich, Switzerland; ²Nationales Zentrum für Mykobakterien, Gloriastrasse 30/32, 8006 Zürich, Switzerland; ³Institut für Klinische Chemie, UniversitätsSpital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland

*Corresponding author. Institut für Medizinische Mikrobiologie, Universität Zürich, Gloriastrasse 30/32, 8006 Zürich, Switzerland. Tel: +41-44-634-26-84; Fax: +41-44-634-49-06; E-mail: psander@imm.uzh.ch

Received 19 April 2017; accepted 9 July 2017,

Objectives: Limited treatment options available for *Mycobacterium abscessus* infections include the parenteral β -lactam antibiotics cefoxitin and imipenem, which show moderate *in vitro* activity. Other β -lactam antibiotics (except meropenem) have no considerable *in vitro* activity, due to their rapid hydrolysis by a broad-spectrum β -lactamase (Bla_{Mab}). We here addressed the impact of β -lactamase production and β -lactam *in vitro* stability on *M. abscessus* MIC results and determined the epidemiological cut-off (ECOFF) values of cefoxitin, imipenem and meropenem.

Methods: By LC high-resolution MS (LC-HRMS), we assessed the *in vitro* stability of cefoxitin, imipenem and meropenem. *M. abscessus* ATCC 19977 strain and its isogenic bla_{Mab} deletion mutant were used for MIC testing. Based on MIC distributions for *M. abscessus* clinical strains, we determined ECOFFs of cefoxitin, imipenem and meropenem.

Results: A functional Bla_{Mab} increased MICs of penicillins, ceftriaxone and meropenem. LC-HRMS data showed significant degradation of cefoxitin, imipenem and meropenem during standard antibiotic susceptibility testing procedures. MIC, MIC₅₀ and ECOFF values of cefoxitin, imipenem and meropenem are influenced by incubation time.

Conclusions: The results of our study support administration of imipenem, meropenem and cefoxitin, for treatment of patients infected with *M. abscessus*. Our findings on *in vitro* instability of imipenem, meropenem and cefoxitin explain the problematic correlation between *in vitro* susceptibility and *in vivo* activity of these antibiotics and question the clinical utility of susceptibility testing of these chemotherapeutic agents.

Introduction

Mycobacterium abscessus is a dreadful and arduous to treat mycobacterial pathogen with a high level of innate resistance to most commercially available antibiotics, including the antituberculous agents.^{1–5} Clinically relevant cases are predominantly associated with pulmonary infections in patients with cystic fibrosis or bronchiectasis and disseminated disease in immunocompromised individuals.^{2–4} *M. abscessus* is also highly resistant to disinfectants and therefore it ordinarily causes skin and soft tissue infections following plastic surgery, tattooing or body piercing.^{3,5–8} Several healthcare-associated outbreaks of *M. abscessus* infections, that have been reported worldwide, highlight the increasing medical importance of this MDR pathogen and the urgent need for reliable medication strategies.^{3,4,9}

As *M. abscessus* clinical isolates are uniformly resistant to standard chemotherapeutic agents, so far, no reliable antibiotic

regimen for *M. abscessus* pulmonary infections has been established. Antibiotic administration is empirical and heavily relies on *in vitro* antibiotic susceptibility testing (AST) by broth microdilution and definitive subspecies identification.^{3,10} The clinical importance of *M. abscessus* subspecies identification (*M. abscessus* subsp. *abscessus*, *M. abscessus* subsp. *bolletii* and *M. abscessus* subsp. *massiliense*) is attributed to the fact that *M. abscessus* subsp. *abscessus* and *M. abscessus* subsp. *bolletii* have a functional inducible erythromycin ribosome methyltransferase gene [erm(41)], which confers macrolide resistance, whereas *M. abscessus* subsp. *massiliense* has a non-functional erm(41), leading to macrolide susceptibility, and thus *M. abscessus* subsp. *massiliense* infections have more favourable prognosis and treatment outcomes.^{10–18} The American Thoracic Society recommends for the treatment of *M. abscessus* lung infections a combination therapy of an oral macrolide (clarithromycin or azithromycin) for clinical isolates susceptible to

macrolides and the intravenous aminoglycoside drug amikacin, administered together with a parenteral β -lactam antibiotic, cefoxitin or imipenem.^{3,19–21} However, with the exception of the macrolide class, very limited data are present in the literature concerning the correlation between AST and the clinical efficacy of these recommended antimycobacterial drugs.²² The clinical relevance of AST remains a controversy, particularly on account of technical problems associated with AST methods, reproducibility of AST results, significant discrepancies between *in vitro* susceptibility and *in vivo* activity of a given drug and solubility and stability issues of the drugs used.²³ Ideally, clinicians could take advantage of AST for *M. abscessus*, when the *in vitro* susceptibility to a drug is consistent with a clinically achievable drug exposure *in vivo*, resulting in favourable treatment outcomes. Accordingly, clinical susceptibility breakpoints must represent MIC distributions and zone diameter distributions for WT and resistant strains, resistance mechanisms, dosing regimens, drug pharmacokinetics, pharmacodynamics and epidemiological cut-off (ECOFF) values and must allow prediction of treatment outcomes.^{22–25} CLSI is the only organization worldwide that has published AST guidelines for rapid growing mycobacteria²⁴ recommending susceptibility testing of amikacin, cefoxitin, ciprofloxacin, clarithromycin, doxycycline or minocycline, imipenem, linezolid, moxifloxacin, trimethoprim/sulfamethoxazole and tobramycin.²⁵ The breakpoint concentrations for these antibiotics have nonetheless been set on the basis of *in vitro* driven studies and their efficacy (except the new drugs linezolid and tigecycline) has been clinically evaluated by Wallace *et al.*²⁶ principally in patients with extrapulmonary disease. To date, EUCAST has not officially announced guiding principles for non-tuberculous mycobacteria susceptibility testing.

Frequently used therapeutics for *M. abscessus* infections are the parenteral β -lactam antibiotics cefoxitin and imipenem,²⁴ which have moderate *in vitro* activity, with MIC values reported by Dub  e *et al.*²⁷ for *M. abscessus* subsp. *abscessus* CIP 104536 of 32 and 8 mg/L, respectively. Meropenem, an ultra-broad-spectrum carbapenem closely related to imipenem,²⁸ displayed a lower MIC value (16 mg/L) than cefoxitin for *M. abscessus* subsp. *abscessus* CIP 104536.²⁷ Most of the other β -lactam antibiotics have no considerable *in vitro* activity due to their rapid hydrolysis by a broad-spectrum class A β -lactamase, encoded by *MAB_2875*, namely *Bla_{Mab}*, which was reported as the major determinant of β -lactam resistance in *M. abscessus*.^{27,29} Determination of the kinetic parameters of this enzyme revealed that it can slowly hydrolyse imipenem and meropenem, while cefoxitin hydrolysis by *Bla_{Mab}* is immensely slow, as the methoxy group at cefoxitin's β -lactam ring was predicted to block the activity of class A β -lactamases.^{27,29,30}

As imipenem, meropenem and cefoxitin are known to have limited *in vitro* stability,³¹ we assessed by LC high-resolution MS (LC-HRMS) the *in vitro* stability of these β -lactams and, by exploiting a *bla_{Mab}* deletion mutant that we generated, we addressed the biological effect of β -lactam stability and β -lactamase production on MIC testing results after different periods of incubation. The direct impact of β -lactam stability on AST testing was further addressed by MIC determination of fresh and pre-incubated β -lactam antibiotics for the ampicillin-susceptible *Escherichia coli* XL1-Blue MRF strain. What is more, based on MIC distributions for *M. abscessus* clinical strains, mainly isolated from respiratory

samples, we estimated ECOFFs of cefoxitin, imipenem and meropenem. Our results show that MIC, MIC₅₀ and ECOFF values of cefoxitin, imipenem and meropenem are severely influenced by stability issues, thus questioning the clinical utility of AST of cefoxitin, imipenem and meropenem, but not the use of these antibiotics in patients with *M. abscessus* infections.

Materials and methods

Bacterial strains and growing conditions

(i) *E. coli* strains were cultivated in LB medium or on LB agar plates, when necessary, containing either ampicillin (120 mg/L) or apramycin (50 mg/L), at 37 °C, overnight. For *E. coli* MIC testing and all cloning steps when constructing the *bla_{Mab}* deletion vector pSE-katG-aac(3)IV- Δ MAB_2875, *E. coli* XL1-Blue MRF (Stratagene, Switzerland) was used. (ii) *M. abscessus* strains were grown in Middlebrook 7H9-OADC-Tween 80 liquid medium or on LB agar plates, when needed, containing either apramycin (50 mg/L) or isoniazid (32 mg/L), at 37 °C, for 5 days. The *M. abscessus* ATCC 19977 type strain, the *M. abscessus* Δ *bla_{Mab}* mutant strain and 62 clinical isolates of *M. abscessus* (33 *M. abscessus* subsp. *abscessus*, 17 *M. abscessus* subsp. *bolletii* and 12 *M. abscessus* subsp. *massiliense* isolates) were used throughout this study. The *M. abscessus* clinical isolates were mainly isolated from respiratory samples that were received at the Swiss National Center for Mycobacteria within the years 2007–14.

Definitive subspecies identification of clinical isolates

Subspecies identification of *M. abscessus* isolates (*M. abscessus* subsp. *abscessus*, *M. abscessus* subsp. *bolletii* and *M. abscessus* subsp. *massiliense*) was based on the 16S rRNA, *rpoB* and *erm*(41) gene sequences.^{12–14,32,33} Subspecies attribution for *M. abscessus* complex isolates was performed according to Tortoli *et al.*¹² The obtained sequences were analysed with the use of Lasergene SeqMan software (DNASTAR, USA), the SmartGene IDNS mycobacteria and *rpoB* databases (SmartGene, Switzerland), and the BLAST algorithm (<http://blast.ncbi.nlm.nih.gov>).

Antibiotics

Imipenem, meropenem, cefoxitin, ceftriaxone, ceftazidime, penicillin G, ampicillin, amoxicillin, amikacin, apramycin and isoniazid were bought from Sigma-Aldrich, Switzerland. All compounds were dissolved in H₂O, according to the manufacturer's recommendations, filter sterilized, aliquoted into stock solutions of 3–50 g/L and finally stored at –20 °C.

Deletion of MAB_2875 in *M. abscessus*

A 1.4 kbp *Hpa*I/*Pfl*23II fragment from position 2926650 to 2928011 (5' *bla_{Mab}* flanking sequence) and a 1.5 kbp *Pfl*23II/*Pfl*23II fragment from position 2928642 to 2930147 (3' *bla_{Mab}* flanking sequence) were PCR amplified using genomic DNA from *M. abscessus* ATCC 19977 (5'-GAAT TAGTTAACAGGTGTGATCCAGATGCCCG-3', 5'-GAATTCGTACGGGCCGCCGAAATCCCTTTCC-3' and 5'-GAAATACGTACGCCATCGTGATGGCGGTACTAC-3', 5'-GAATTCGTACGGGTGTCTACAGTCTTGACACAC-3', respectively) and cloned into the pSE-katG-aac(3)IV vector with corresponding enzymes, resulting in the *bla_{Mab}* deletion vector pSE-katG-aac(3)IV- Δ MAB_2875. *M. abscessus* *bla_{Mab}* deletion mutant was generated using a double selection strategy described previously in detail by Rominski *et al.*^{34,35} In brief, pSE-katG-aac(3)IV- Δ MAB_2875 was transformed into electrocompetent *M. abscessus* ATCC 19977. Competent cells (100 μ L) were mixed with 1–2 μ g of plasmid DNA (supercoiled) and electroporated in a Bio-Rad Gene pulser II using 4 mm gap electroporation cuvettes and the settings: 2.5 kV, 1000 Ω and 25 μ F.³⁶ Cells were resuspended after electroporation in 0.9 mL of 7H9-OADC-Tween 80 liquid medium and incubated for 5 h at 37 °C. Proper dilutions were eventually

plated on selective agar and, after 5 days of incubation, single colonies were picked and restreaked on LB agar plates with appropriate antibiotics. Transformants were selected on LB agar plates containing apramycin and identified by *aac(3)IV* colony PCR (primers: 5'-CACCTTCTTACGAGG CAGACCTC-3' and 5'-GGTCTGACGCTCATGGAAGTAGTAGG-3'). Isolation of genomic DNA was performed by phenol-chloroform-isoamyl alcohol extraction as described previously³⁷ and single crossover transformants were confirmed by Southern blot analysis with a 0.45 kbp *SacI* 3'*bla_{Mab}* DNA probe and subjected to counterselection on LB agar plates containing isoniazid. Single colonies were screened for deletion of *MAB_2875* by PCR (primers: 5'-GTACACCGTCTTCGGGACG-3' and 5'-GAAAGTGCGAGTACGCGTCTG-3') and their genotype was finally verified by Southern blot analysis using the same 0.45 kbp *SacI* 3'*bla_{Mab}* DNA probe. In this way, a 0.63 kbp region of the *MAB_2875* was deleted from the genome of *M. abscessus* ATCC 19977.

Nitrocefin test

For the detection of β -lactamase production in the *M. abscessus* ATCC 19977 type strain and the Δ *bla_{Mab}* mutant strain we performed a chromogenic nitrocefin test (Becton Dickinson, USA). Tubes containing (i) pure nitrocefin solution, (ii) nitrocefin solution inoculated with five colonies of the *M. abscessus* ATCC 19977 type strain and (iii) nitrocefin solution inoculated with five colonies of the *M. abscessus* Δ *bla_{Mab}* mutant were incubated for 1 h at room temperature before a photo was taken.

MIC assays

MIC assays were performed with the microdilution method and according to CLSI guidelines,²⁵ but with incubation of the 96-well microtitre plates at 37 °C, as described previously.^{34,35} Directly after the preparation of the antibiotic stock solutions, working solutions were prepared by diluting the corresponding stock solutions in CAMHB (pH 7.4) (Becton Dickinson, Switzerland) to a concentration of 512 mg/L (final antibiotic concentration used for AST; 256 mg/L) and were subsequently stored at -80 °C. Shortly before the conduct of an MIC experiment (day 0), working solutions were thawed for the first time and were directly used. Alternatively, working solutions were thawed and pre-incubated for 1–7 days at 37 °C and their inhibitory effect was compared with freshly thawed antibiotics. Two-fold serial dilutions of the freshly thawed (and pre-incubated: for the pre-incubation MIC experiments) working solutions were prepared using CAMHB in sterile 96-well microtitre plates (Greiner Bio-One, Switzerland). Each 96-well microtitre plate included a positive growth control lacking antibiotic and a sterile negative control containing only CAMHB. To achieve a final inoculum titre of 1–5 × 10⁵ cfu/mL, while final volume per well was 100 μ L, bacterial suspensions of strains with smooth or rough phenotypes were adjusted to a McFarland standard of 0.5 and 3.0, respectively, and subsequently diluted in CAMHB. The proper titre of the inocula was confirmed by obtaining cfu counts on LB agar plates. MIC values were assessed by visual inspection after incubation at 37 °C for 16 h for *E. coli* strains and 3, 5, 7 and 12 days for *M. abscessus*. MIC assays for *E. coli*, *M. abscessus* ATCC 19977 and the *M. abscessus* *bla_{Mab}* deletion mutant were conducted in triplicate. MIC assays for *M. abscessus* complex clinical isolates were performed once.

LC-HRMS assays

In vitro antimicrobial stability of cefoxitin, imipenem and meropenem was evaluated using CAMHB and the maximum final antibiotic concentration used for AST (256 mg/L). A different test tube was prepared for each antibiotic and for every reading timepoint, i.e. 3, 5, 7 and 12 days. A day 0 control was used to define the 100% relative antibiotic concentration. The antibiotic-containing test tubes were incubated under the same temperature conditions as the microtitre plates used for AST (37 °C). Cefoxitin, imipenem and meropenem were quantified by LC-HRMS on a Q Exactive hybrid instrument (Thermo Fisher, Switzerland). Samples were precipitated using a precipitation solution consisting of methanol/acetonitrile (80/20, v/v),

containing the corresponding stable-isotope labelled internal standards. After centrifugation at 11 700 g for 10 min at 4 °C, 10 μ L of the clear supernatant was injected into the turbulent flow online extraction system. As extraction column a Cyclone column (50 × 0.5 mm) was used and for analytical chromatography a Hypersil Gold C8 column (100 × 3 mm) was used. Mobile phases consisted of 10 mM ammonium acetate in water + 0.1% formic acid and 10 mM ammonium acetate in methanol/acetonitrile (50/50, v/v) + 0.1% formic acid. Samples were analysed in positive heated electrospray ionization mode and detection was done in full-scan mode with a resolution of 70 000 full width at half maximum (calculated for *m/z* 200).

ECOFF determination

MIC data for 62 *M. abscessus* complex clinical isolates were collected and the resistance population analysis charts were calculated using the integrated histographical analysis tool of Microsoft Excel. Median MIC₅₀ values of cefoxitin, imipenem and meropenem for the *M. abscessus* complex clinical strains were calculated using SPSS software. All ECOFF values were determined by the eyeball method.^{38,39}

Results and discussion

Generation of the *M. abscessus* *MAB_2875* deletion mutant



Similarly to our previously published techniques,^{34,35} we intended to generate an *M. abscessus* Δ *MAB_2875* mutant, which would enable us to address directly the role of the β -lactamase production of *M. abscessus* on MIC testing results of β -lactam antibiotics. The *bla_{Mab}* deletion mutant was constructed by transformation of *M. abscessus* ATCC 19977 with plasmid pSE-*katG-aac(3)IV-ΔMAB_2875* applying an apramycin-positive selection⁴⁰ and a *katG*-dependent isoniazid counterselection strategy (Figure 1a).^{34,35} Deletion of *MAB_2875* was confirmed by Southern blot analysis (Figure 1b). While this study was ongoing, a Δ *MAB_2875* mutant was also generated by Dubée et al.,²⁷ but with different cloning, genetic manipulation and selection strategies.

M. abscessus *bla_{Mab}* deletion mutant is deficient in β -lactamase production

To assess the β -lactamase production of the *M. abscessus* Δ *bla_{Mab}* mutant, we performed a chromogenic nitrocefin test. The cephalosporin nitrocefin changes colour from yellow to red in the presence of β -lactamases that hydrolyse the amide bond in its β -lactam ring.⁴¹ As Figure 2 shows, the tube containing yellow pure nitrocefin solution (Figure 2a) did not change colour. The tube containing nitrocefin solution inoculated with *M. abscessus* ATCC 19977 (Figure 2b) changed colour and became red, while the tube containing nitrocefin solution inoculated with the *M. abscessus* Δ *bla_{Mab}* mutant (Figure 2c) stayed yellow, confirming that the *M. abscessus* *bla_{Mab}* deletion mutant is deficient in β -lactamase production. These results align with the findings from Dubée et al.,²⁷ who reported *Bla_{Mab}* as the single determinant of β -lactam resistance in *M. abscessus*.

AST of *M. abscessus* Δ *MAB_2875*

To explore the role of *Bla_{Mab}* in *M. abscessus* β -lactam resistance, MIC values for the *M. abscessus* ATCC 19977 type strain and the *M. abscessus* Δ *bla_{Mab}* mutant were determined with the microdilution method for the β -lactam antibiotics, imipenem,



antibiotics tested except imipenem, meropenem and ceftazidime. Deletion of *bla*_{Mab} significantly reduced the MIC values of all penicillins tested (penicillin G, ampicillin and amoxicillin) and the cephalosporin ceftriaxone. MIC values of ≥ 256 mg/L of the oxyimino-cephalosporin ceftazidime for both *M. abscessus* ATCC 19977 and the *M. abscessus* Δ *bla*_{Mab} mutant suggest that ceftazidime is not active against *M. abscessus*. Cefoxitin MIC values of 32 mg/L (day 3) for both *M. abscessus* ATCC 19977 and the Δ *bla*_{Mab} mutant (Table 1) agree with earlier reported data,²⁷ corroborating previous molecular modelling and structural analyses,⁴² which delineated that substitutions of the β -lactam ring by a methoxy group in cefoxitin inhibits the activity of class A β -lactamases.³⁰ As expected, amikacin MICs were independent of the *bla* genotype.

To date, none of the recent studies on β -lactam susceptibility testing of *M. abscessus* CIP 104536 and the *M. abscessus* Δbla_{Mab} mutant has reported MIC data obtained after 3 days of incubation.^{27,29,30,43,44} Indeed, CLSI guidelines²⁵ for imipenem MIC testing for rapid growing mycobacteria recommends a maximum incubation period of 3 days and state that ‘the reported breakpoints for imipenem are considered tentative’. Our observation that imipenem, meropenem and cefoxitin MIC values rise substantially with the incubation time for both the *M. abscessus* ATCC 19977 strain and the *M. abscessus* Δbla_{Mab} mutant (Table 1), in correlation with the fact that certain antibiotics undergo partial degradation

under *in vitro* testing conditions,⁴⁵ led us to investigate further the effect of the β -lactam stability on MIC testing procedures.

Effect of β -lactam stability on *E. coli* MIC testing

To determine experimentally whether the results of the *M. abscessus* MIC testing of β -lactams after 3, 5 and 7 days of incubation clearly reflect β -lactamase production or are affected by

Table 1. AST results of *M. abscessus* WT and Δbla_{Mab} mutant (broth microdilution method)

Antibiotic	MIC (mg/L)							
	<i>M. abscessus</i> ATCC 19977				<i>M. abscessus</i> Δbla_{Mab}			
	day 3	day 5	day 7	day 12	day 3	day 5	day 7	day 12
Imipenem	2	4	8	64	1	2	4	64
Meropenem	8	16	32	256	2	4	4	16
Cefoxitin	32	32	64	128	32	32	32	128
Ceftriaxone	64	64	64	64	8	16	16	16
Ceftazidime	>256	>256	>256	>256	256	>256	>256	>256
Penicillin G	>256	>256	>256	>256	2	4	4	4
Ampicillin	>256	>256	>256	>256	4	4	8	8
Amoxicillin	>256	>256	>256	>256	2	4	4	4
Amikacin	1	2	4	8	1	2	4	8

instability of the antibiotics tested, we performed an MIC experiment using the *E. coli* XL1-Blue model strain, which produces no β -lactamases, and fresh and pre-incubated (at 37 °C, for 1–7 days) β -lactam antibiotics. In that way, all MIC results could be obtained after 16 h of incubation of the microtitre plates and putative MIC differences between the fresh and the pre-incubated antibiotics could be directly correlated to instability of the tested antibiotics. Our results show that pre-incubation at 37 °C affects MIC results of imipenem, meropenem and to a lesser extent cefoxitin and ceftazidime (Figure 3a and b), whereas the MIC results of ceftriaxone, penicillin G, ampicillin, amoxicillin and as expected the control stable aminoglycoside antibiotic amikacin are not influenced by pre-incubation (Figure 3b, c and d). By assuming that drug degradation follows an exponential decay process and using the data displayed in Figure 3, we calculated the half-life values of imipenem as 0.75 days, of meropenem as 1.5 days and of cefoxitin as 3 days. We therefore conclude that the increased MIC values of the pre-incubated antibiotics, already before day 3, reflect instability of the antibiotics. Reading of *M. abscessus* MICs at day 3 and later gives a *de facto* misleading impression for the true extent of activity of imipenem, meropenem and cefoxitin.

In vitro antimicrobial stability of cefoxitin, imipenem and meropenem by LC-HRMS

Based on our results suggesting that incubation of cefoxitin, imipenem and meropenem at 37 °C gives rise to misleading MIC




Figure 3. MIC values for *E. coli* XL1-Blue strain of fresh and pre-incubated (at 37 °C, for 1–7 days) β -lactam antibiotics. (a) Carbapenems: imipenem and meropenem. (b) Cephalosporins: cefoxitin, ceftriaxone and ceftazidime. (c) Penicillins: penicillin G, ampicillin and amoxicillin. (d) Aminoglycoside (control): amikacin.

results, we intended to address the *in vitro* stability of these β -lactams, by quantifying them using LC-HRMS. Tubes containing CAMHB and the maximum antibiotic concentration used for AST (256 mg/L) were incubated at 37 °C. The 100% relative antibiotic concentration of each antibiotic was defined by a day 0 control tube. On days 3, 5, 7 and 12 the concentrations of ceftazidime, imipenem and meropenem were quantified. Data obtained by the LC-HRMS method, clearly show degradation of ceftazidime, imipenem and meropenem. Particularly, the relative concentration on day 3 for imipenem dramatically dropped to 3.3%, whereas for ceftazidime and meropenem it dropped to 36.6% and 35.6%, respectively (Figure 4e, j and o). By using the results of this assay, the calculated half-life of imipenem was 0.6 days, that of meropenem was 2 days and that of ceftazidime was 2.1 days. These findings agree with those deducted from the *E. coli* MIC testing and confirm that the MIC values of ceftazidime, imipenem and meropenem for *M. abscessus* on day 3 and later are misleading, as concentration of the active compound is lowered. Particularly for imipenem, MIC₅₀ on day 3 was 16 mg/L (Figure 4j). However, growth inhibition of half of the clinical isolates was in reality achieved by considerably lower drug amounts, as the true active relative concentration of imipenem shrank to 3.3% by day 3 due to the short half-life of this antibiotic. Consequently, due to instability of imipenem, meropenem and ceftazidime, *M. abscessus* MIC determination after 3 days of incubation does not reflect the potency of these three compounds, particularly as clinical administration³ of these drugs is daily and in multiple doses. These data, on the one hand, question the utility of susceptibility testing of imipenem, meropenem and ceftazidime, but, on the other hand, support administration of these parenteral β -lactam antibiotics as part of combinational regimens for the treatment of *M. abscessus* infections.

ECOFF values of ceftazidime, imipenem and meropenem for *M. abscessus* complex

According to EUCAST, for the determination of clinical susceptibility breakpoint values and improvement of the MIC interpretation for clinical isolates, ECOFFs need to be defined to separate the WT population from any non-WT strains with acquired drug resistance mechanisms to the chemotherapeutic agents in question.⁴⁶ We therefore endeavoured to estimate ECOFF values of ceftazidime, imipenem and meropenem by visual inspection of the MIC histographic distribution analysis (eyeball method)^{36,37} for 62 *M. abscessus* complex clinical strains isolated from respiratory samples, after 3, 5, 7 and 12 days of incubation at 37 °C (Figure 4). The results show that MIC distributions for our collection of *M. abscessus* complex isolates of ceftazidime, imipenem and meropenem are close to the breakpoints established by CLSI and that the eyeball-estimated ECOFF values did not show a separation of the *M. abscessus* complex isolates into two distinct subgroups, WT and resistotype. ECOFFs were set at the highest MIC value observed among the isolates tested and all of these isolates are therefore classified in the WT subgroup. According to this classification, a putative clinical isolate with an additional β -lactam resistance mechanism would have a very high MIC value (higher than the corresponding ECOFF) that would be neither detected by standard AST laboratory procedures nor relevant for clinical interpretation. Interestingly, the presence or absence of a functional or non-functional β -lactamase in

M. abscessus could not be predicted by the MIC distribution for the clinical isolates, as the MIC values determined for *M. abscessus* Δ bla_{Mab} (Table 1) fall in the MIC distribution for the 'WT' subgroup of clinical isolates of all three β -lactams (Figure 4).

Furthermore, our results show that MIC and MIC₅₀ values of ceftazidime, imipenem and meropenem are greatly influenced by incubation time; the longer the incubation period, the higher the MIC for the individual strains, the MIC₅₀ and the estimated ECOFF values (Figure 4). The presented MIC distribution bars, as well as the MIC₅₀ and ECOFF lines, would represent valid data for MIC, MIC₅₀ and ECOFF values, only if the drugs were 100% stable. However, according to the LC-HRMS results, ceftazidime, meropenem and particularly imipenem were proven as unstable compounds and thus MIC values for the *M. abscessus* complex clinical isolates of these three β -lactams on day 3 and later are certainly overestimated, as already discussed. If the concentration of the biological active form of the drug could have been kept constant during the AST procedures, we expect that the position of the MIC distribution bars and MIC₅₀ and ECOFF lines would be shifted to the left in all MIC distribution analysis graphs (Figure 4). Our observations highlight the impact of ceftazidime, imipenem and meropenem stability issues on MIC, MIC₅₀ and ECOFF determination for *M. abscessus* complex clinical isolates.

Conclusions

Taken together, our study confirmed Bla_{Mab} as the major determinant of innate β -lactam resistance in *M. abscessus* and addressed experimentally the biological effect of β -lactamase production and β -lactam stability on *M. abscessus* MIC testing results after different incubation periods. Our results show that MIC, MIC₅₀ and ECOFF values of ceftazidime, imipenem and meropenem are immensely influenced by incubation time. LC-HRMS data and MIC determination of pre-incubated drugs for the fast growing model organism (*E. coli*) proved significant degradation of ceftazidime, imipenem and meropenem during standard AST procedures, explaining the problematic correlation between *in vitro* susceptibility of these three β -lactams and their *in vivo* activity. Our findings critically question the clinical utility of ceftazidime, imipenem and meropenem susceptibility testing, but further support administration of these chemotherapeutic agents for the treatment of *M. abscessus* infections.

Acknowledgements

We thank C. Castelberg for technical assistance regarding MIC determinations for clinical strains. We acknowledge F. Maurer and A. Somoskovi for their help and critical thinking in the initial phase of the study.

Funding

This study was supported in part by the University of Zürich, Institute of Medical Microbiology and a grant from the Swiss National Science Foundation (#31003A_153349) to P. S.

Transparency declarations

None to declare.




Figure 4. MIC distributions of cefoxitin (a–d), imipenem (f–i) and meropenem (k–n) for *M. abscessus* complex strains ($n = 62$). MIC₅₀ values are indicated by a black vertical continuous line, whereas ECOFF values are indicated by a black vertical broken line. *, MIC values for the *M. abscessus* ATCC 19977 type strain; Δ, MIC values for the *M. abscessus* Δ*bla*_{Mab} mutant. Drug stability of cefoxitin (e), imipenem (j) and meropenem (o) in comparison with median MIC₅₀ values. (e, j and o) Crosses connected with a black continuous line show relative drug concentrations and filled circles connected with a black broken line show MIC₅₀ values.

References

- 1 De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. *Clin Infect Dis* 2006; **42**: 1756–63.
- 2 Brown-Elliott BA, Wallace RJ Jr. Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria. *Clin Microbiol Rev* 2002; **15**: 716–46.
- 3 Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007; **175**: 367–416. Erratum in: *Am J Respir Crit Care Med* 2007; **175**: 744–5.
- 4 Bryant JM, Grogono DM, Rodriguez-Rincon D et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. *Science* 2016; **354**: 751–7.
- 5 Nessar R, Cambau E, Reyat JM et al. *Mycobacterium abscessus*: a new antibiotic nightmare. *J Antimicrob Chemother* 2012; **67**: 810–8.
- 6 Maurer F, Castelberg C, von Braun A et al. Postsurgical wound infections due to rapidly growing mycobacteria in Swiss medical tourists following cosmetic surgery in Latin America between 2012 and 2014. *Euro Surveill* 2014; **19**: pii=20905.
- 7 Bechara C, Macheras E, Heym B et al. *Mycobacterium abscessus* skin infection after tattooing: first case report and review of the literature. *Dermatology* 2010; **221**: 1–4.
- 8 Trupiano JK, Sebek BA, Goldfarb J et al. Mastitis due to *Mycobacterium abscessus* after body piercing. *Clin Infect Dis* 2001; **33**: 131–4.
- 9 Marras TK, Mendelson D, Marchand-Austin A et al. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998–2010. *Emerg Infect Dis* 2013; **19**: 1889–91.
- 10 Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians' perspectives. *Tuberc Respir Dis (Seoul)* 2016; **79**: 74–84.
- 11 Benwill JL, Wallace RJ Jr. *Mycobacterium abscessus*: challenges in diagnosis and treatment. *Curr Opin Infect Dis* 2014; **27**: 506–10.
- 12 Tortoli E, Kohl TA, Brown-Elliott BA et al. Emended description of *Mycobacterium abscessus*, *Mycobacterium abscessus* subsp. *abscessus* and *Mycobacterium abscessus* subsp. *bolletii* and designation of *Mycobacterium abscessus* subsp. *massiliense* comb. nov. *Int J Syst Evol Microbiol* 2016; **66**: 4471–9.
- 13 Maurer FP, Castelberg C, Quiblier C et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of *Mycobacterium abscessus*. *J Antimicrob Chemother* 2014; **69**: 1559–63.
- 14 Kim HY, Kim BJ, Kook Y et al. *Mycobacterium massiliense* is differentiated from *Mycobacterium abscessus* and *Mycobacterium bolletii* by erythromycin ribosome methyltransferase gene (*erm*) and clarithromycin susceptibility patterns. *Microbial Immunol* 2010; **54**: 347–53.
- 15 Cho YJ, Yi H, Chun J et al. The genome sequence of 'Mycobacterium massiliense' strain CIP 108297 suggests the independent taxonomic status of the *Mycobacterium abscessus* complex at the subspecies level. *PLoS One* 2013; **8**: e81560.
- 16 Sassi M, Drancourt M. Genome analysis reveals three genomospecies in *Mycobacterium abscessus*. *BMC Genomics* 2014; **15**: 359.
- 17 Heydari H, Wee WY, Lokanathan N et al. MabsBase: a *Mycobacterium abscessus* genome and annotation database. *PLoS One* 2013; **8**: e62443.
- 18 Nash KA, Andini N, Zhang Y et al. Intrinsic macrolide resistance in rapidly growing mycobacteria. *Antimicrob Agents Chemother* 2006; **50**: 3476–8.
- 19 American Thoracic Society statement: diagnosis and treatment of disease caused by nontuberculous mycobacteria. *Am J Respir Crit Care Med* 1997; **156**: S1–25.
- 20 Daley CL, Griffith DE. Pulmonary disease caused by rapidly growing mycobacteria. *Clin Chest Med* 2002; **23**: 623–32.
- 21 Colombo RE, Olivier KN. Diagnosis and treatment of infections caused by rapidly growing mycobacteria. *Semin Respir Crit Care Med* 2008; **29**: 577–88.
- 22 van Ingen J, Kuijper EJ. Drug susceptibility of nontuberculous mycobacteria. *Future Microbiol* 2014; **9**: 1095–110.
- 23 van Ingen J, Boeree MJ, van Soolingen D et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. *Drug Resist Updat* 2012; **15**: 149–61.
- 24 Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. *Clin Microbiol Rev* 2012; **25**: 545–82.
- 25 Clinical and Laboratory Standards Institute. *Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes—Second Edition: Approved Standard M24-A2*. CLSI, Wayne, PA, USA, 2011.
- 26 Wallace RJ Jr, Nash DR, Steele LC et al. Susceptibility testing of slow growing mycobacteria by a microdilution MIC method with 7H9 broth. *J Clin Microbiol* 1986; **24**: 976–81.
- 27 Dub  e V, Bernut A, Cortes M et al. β -Lactamase inhibition by avibactam in *Mycobacterium abscessus*. *J Antimicrob Chemother* 2015; **70**: 1051–8.
- 28 Zhanel GG, Simor AE, Vercaigne L et al. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. *Can J Infect Dis* 1998; **9**: 215–28.
- 29 Soroka D, Dub  e V, Soulier-Escrihuela O et al. Characterization of broad-spectrum *Mycobacterium abscessus* class A β -lactamase. *J Antimicrob Chemother* 2014; **69**: 691–6.
- 30 Ramirez A, Ruggiero M, Aranaga C et al. Biochemical characterization of β -lactamases from *Mycobacterium abscessus* complex and genetic environment of the β -lactamase-encoding gene. *Microb Drug Resist* 2017; **23**: 294–300.
- 31 Somoskovi A, Salfinger M. Nontuberculous mycobacteria in respiratory infections: advances in diagnosis and identification. *Clin Lab Med* 2014; **34**: 271–95.
- 32 Adekambi T, Colson P, Drancourt M. *rpoB*-based identification of nonpigmented and late-pigmenting rapidly growing mycobacteria. *J Clin Microbiol* 2003; **41**: 5699–708.
- 33 Springer B, Stockman L, Teschner K et al. Two-laboratory collaborative study on identification of mycobacteria: molecular versus phenotypic methods. *J Clin Microbiol* 1996; **34**: 296–303.
- 34 Rominski A, Roditscheff A, Selchow P et al. Intrinsic rifamycin resistance of *Mycobacterium abscessus* is mediated by ADP-ribosyltransferase MAB_0591. *J Antimicrob Chemother* 2017; **72**: 376–84.
- 35 Rominski A, Selchow P, Becker K et al. Elucidation of *Mycobacterium abscessus* aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes. *J Antimicrob Chemother* 2017; **72**: 2191–200.
- 36 Sander P, Papavinasasundaram KG, Dick T et al. *Mycobacterium bovis* BCG *recA* deletion mutant shows increased susceptibility to DNA-damaging agents but wild-type survival in a mouse infection model. *Infect Immun* 2001; **69**: 3562–8.
- 37 Sander P, Meier A, B  ttger EC. *rpsL*⁺: a dominant selectable marker for gene replacement in mycobacteria. *Mol Microbiol* 1995; **16**: 991–1000.
- 38 Turnidge J, Kahlmeter G, Kronvall G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. *Clin Microbiol Infect* 2006; **12**: 418–25.
- 39 Keller PM, H  mke R, Ritter C et al. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in *Mycobacterium tuberculosis* using the MGIT 960 system equipped with TB eXIST. *Antimicrob Agents Chemother* 2015; **59**: 4352–5.

- 40** Pawlik A, Garnier G, Orgeur M et al. Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent *Mycobacterium abscessus*. *Mol Microbiol* 2013; **90**: 612–29.
- 41** Hrabák J, Chudáčková E, Papagiannitsis CC. Detection of carbapenemases in Enterobacteriaceae: a challenge for diagnostic microbiological laboratories. *Clin Microbiol Infect* 2014; **20**: 839–53.
- 42** Matagne A, Lamotte-Brasseur J, Dive G et al. Interactions between active-site-serine β -lactamases and compounds bearing a methoxy side chain on the α -face of the β -lactam ring: kinetic and molecular modelling studies. *Biochem J* 1993; **293**: 607–11.
- 43** Lefebvre AL, Dubée V, Cortes M et al. Bactericidal and intracellular activity of β -lactams against *Mycobacterium abscessus*. *J Antimicrob Chemother* 2016; **71**: 1556–63.
- 44** Soroka D, Ourghanlian C, Compain F et al. Inhibition of β -lactamases of mycobacteria by avibactam and clavulanate. *J Antimicrob Chemother* 2017; **72**: 1081–8.
- 45** Wick WE. Influence of antibiotic stability on the results of in vitro testing procedures. *J Bacteriol* 1964; **87**: 1162–70.
- 46** Ängeby K, Juréen P, Kahlmeter G et al. Challenging a dogma: antimicrobial susceptibility testing breakpoints for *Mycobacterium tuberculosis*. *Bull World Health Organ* 2012; **90**: 693–8.